ALGSEarnings•globenewswire•
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
Sentiment:Positive (65)
Summary
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 6, 2025 by globenewswire